United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, llc dba vangard labs - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate tablet in indicated in adult and pediatric patients for the: - treatment of uncomplicated malaria due to plasmodium falciparum, plasmodium malariae, plasmodium vivax, and plasmodium ovale. - prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use: hydroxychloroquine sulfate tablet is not recommended for: - treatment of complicated malaria. - treatment of malaria by chloroquine or hydroxychloroquine-resistant strains of plasmodium species [see microbiology (12.4)]. - treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium species has not been identified. - prophylaxis of malaria in geographic areas where chloroquine resistance occurs. - prevention of relapses of p. vivax or p. ovale because it is not active against the hypnozoite liver stage forms of these parasites. for radical cure of p. vivax and p. ovale infections, concomitant therapy with an 8-aminoquinoline dr

United States - English - NLM (National Library of Medicine)

chartwell rx, llc - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate tablets are indicated for the: - treatment of uncomplicated malaria due to susceptible strains of p. falciparum, p. malariae, p. ovale, and p. vivax . - prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. - treatment of extraintestinal amebiasis. chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. limitations of use in malaria: - do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). - do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, resistance to chloroquine phosphate tablets is widespread in p. falciparum , and is reported in p. vivax (see warnings). - concomitant therapy with an 8-aminoquinoline drug is necessary for treat

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - hydroxychloroquine sulfate, quantity: 200 mg - tablet - excipient ingredients: colloidal anhydrous silica; calcium hydrogen phosphate; magnesium stearate; hypromellose; polysorbate 80; pregelatinised maize starch; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - rheumatoid arthritis; mild systemic and discoid lupus erythematosus; the suppression and treatment of malaria.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydroxychloroquine sulfate -

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - malaria hydroxychloroquine sulfate is indicated for the treatment of uncomplicated malaria due to p. falciparum, p. malariae, p. ovale, and p. vivax . hydroxychloroquine sulfate is indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use in malaria • hydroxychloroquine sulfate is not recommended for the treatment of complicated malaria. • hydroxychloroquine sulfate is not effective against chloroquine or hydroxychloroquine-resistant strains of plasmodium species (see clinical pharmacology – microbiology). hydroxychloroquine sulfate is not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium species has not been identified. • hydroxychloroquine sulfate is not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. • hydroxychloroquine sulfate does not prevent relapses of p. vivax or p. ovale because it is not active against th

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - malaria hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to p. falclparum, p. malariae, p. ovale, and p. vlvax. hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use in malaria prior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria, consult the centers for disease control and prevention (cdc) malaria website (http://www.cdc.gov/malaria). lupus erythematosus hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. rheumatoid arthritis hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. use of hydroxychloroquine sulfate tablets is contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds.

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - malaria hydroxychloroquine sulfate is indicated for the treatment of uncomplicated malaria due to p. falciparum, p. malariae, p. ovale, and p. vivax . hydroxychloroquine sulfate is indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use in malaria • hydroxychloroquine sulfate is not recommended for the treatment of complicated malaria. • hydroxychloroquine sulfate is not effective against chloroquine or hydroxychloroquine-resistant strains of plasmodium species (see clinical pharmacology – microbiology). hydroxychloroquine sulfate is not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium species has not been identified. • hydroxychloroquine sulfate is not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. • hydroxychloroquine sulfate does not prevent relapses of p. vivax or p. ovale because it is not active against th

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - malaria   hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to p. falciparum , p. malariae , p. ovale , and p. vivax . hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use in malaria - hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malaria. - hydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquine-resistant strains of plasmodium species (see clinical pharmacology – microbiology ). hydroxychloroquine sulfate tablets are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium species has not been identified. - hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. - hy

United States - English - NLM (National Library of Medicine)

cardinal health 107, llc - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - malaria   hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to p. falciparum , p. malariae , p. ovale , and p. vivax . hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use in malaria prior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria, consult the centers for disease control and prevention (cdc) malaria website (http://www.cdc.gov/malaria). lupus erythematosus hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. rheumatoid arthritis hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. use of hydroxychloroquine sulfate is contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds.

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - chloroquine phosphate (unii: 6e17k3343p) (chloroquine - unii:886u3h6uff) - chloroquine phosphate tablets are indicated for the: - treatment of uncomplicated malaria due to susceptible strains of p. falciparum, p.malariae, p. ovale, and p.vivax . - prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. - treatment of extraintestinal amebiasis. chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. limitations of use in malaria: - do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). - do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, resistance to chloroquine phosphate tablets is widespread in p. falciparum, and is reported in p.vivax (see warnings). - concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stag